⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463730 | 1.00 | — | — | |
| SCHEMBL7186214 | 1.00 | — | — | |
| SCHEMBL1707149 | 1.00 | — | — | |
| SCHEMBL8932029 | 1.00 | — | — | |
| SCHEMBL1578014 | 1.00 | — | — | |
| SCHEMBL24868052 | 1.00 | — | — | |
| SCHEMBL18398206 | 1.00 | — | — | |
| SCHEMBL1463728 | 1.00 | — | — | |
| SCHEMBL11939917 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28405061 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365546-A1 | 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ORIGIANT PHARMACEUTICAL CO., LTD (CN) | 2023-11-16 | — | — | US | disclosed |
| EP-3856724-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20210139454-A1 | FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| EP-3004082-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191929-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-04 | — | — | WO | disclosed |
| EP-2651899-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080284-A2 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |